Home
»
Press Room
»
Myomectomy Market Size Worth USD 1.1 Billion By 2027

Myomectomy Market Size Worth USD 1.1 Billion By 2027 | CAGR 9.1%

September 2020 | Report Format: Electronic (PDF)

Myomectomy Market Growth & Trends

The global myomectomy market size is anticipated to reach USD 1.1 billion by 2027, expanding at a CAGR of 9.1%, according to a new report by Grand View Research, Inc. An increasing number of patients suffering from health issues such as uterine fibroids, endometriosis, and chronic pelvic pain are factors driving the market.

Myomectomy is the surgical method to eradicate fibroids without affecting the healthy tissue of the uterus. Fibroids majorly develop in 50.0% of women, which have led to increased demand for the procedure and it preserves the uterus, unlike hysterectomy. Therefore, it is considered the standard of care for eliminating fibroids. This is anticipated to boost market growth over the forecast period.

Moreover, increased patient preference for less invasive treatments is expected to boost the market growth. Nowadays, minimally invasive treatment options for the procedure include laparoscopic or robotic, and hysteroscopic myomectomy. All these techniques are minimally invasive and eliminate the need for general anesthesia. These procedures also cause less discomfort and post-operative pain.

Furthermore, the incorporation of new technologies and the introduction of new products by market players are expected to boost market growth during the forecast period. For instance, Intuitive Surgical has launched the Single Port Platform”-da Vinci SP Surgical System. It enables doctors with robotic-assisted technology intended for deep and narrow access to tissue during various urological procedures.

Request a free sample copy or view report summary: Myomectomy Market Report

Myomectomy Market Report Highlights

Based on type, the abdominal myomectomy segment dominated the market with a share of 39.4% in 2019, as this procedure is the established permanent solution for large fibroids growing in the uterine wall
On the basis of product, others segment dominated the overall market with a share of 36.64% in 2019. Since, this segment offers benefits such as same-day procedure, less invasive treatment, and faster recovery as compared to other products
North America dominated the market with a major share of 53.05% in 2019 owing to the increasing uterus related illnesses in the region and availability of the latest treatment procedures.